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Van Trommel et al have previously shown that serum human chorionic gonadotropin (hCG) cutoff levels can provide early prediction
of resistance to first-line methotrexate (MTX) in patients with persistent trophoblastic disease (PTD). In this study, we validate this
approach of prediction of resistance to single-agent chemotherapy in an independent and larger cohort of PTD patients using a
different hCG assay. Receiver operating characteristics (ROC) curves were constructed to determine hCG cutoff levels and sensitivity
between patients cured on single-agent chemotherapy (control group) and patients requiring change to combination chemotherapy
(study group). Receiver operating characteristics analysis identified an hCG cutoff value of 737IUl
 1 that enabled us to predict the
subsequent development of single-agent chemotherapy resistance in 52% of patients before their fourth MTX course at 97.5%
specificity. This would have enabled an earlier switch to combination chemotherapy reducing the MTX exposure by an average of
2.5 courses. The present findings confirm that serum hCG cutoff levels predict resistance to single-agent therapy earlier than
traditional methods. Change to combination chemotherapy should be considered for patients whose serum hCG levels exceed these
hCG cutoff values. For patients not exceeding the hCG cutoff levels, static or rising hCG levels should still be included in the criteria
for change of chemotherapy.
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Human chorionic gonadotropin (hCG) is a sensitive marker in
monitoring trophoblastic activity in gestational trophoblastic
disease (GTD; Delfs, 1957). Persistent trophoblastic disease
(PTD) is a clinical diagnosis, based on static or rising hCG levels
following uterine evacuation of hydatidiform mole. The Interna-
tional Federation of Obstetrics and Gynecology (FIGO) defines
PTD as static hCG levels in four consecutive blood samples, a
rising hCG concentration in three consecutive samples or persis-
tence of elevated hCG levels for more than 6 months after evacu-
ation (FIGO Oncology Committee, 2002). Persistent trophoblastic
disease occurs most commonly after complete hydatidiform moles
(15%), although partial hydatidiform moles may also transform
into malignant GTD (0.5%; Seckl et al, 2000; Wolfberg et al, 2004).
Depending on their prognostic risk category, patients are generally
treated with first-line single-agent chemotherapy (methotrexate
(MTX) or actinomycin D) in case of low-risk disease or first-line
EMA/CO combination chemotherapy (etoposide, MTX, actinomy-
cin D, cyclophosphamide and oncovin) in case of high-risk PTD
(FIGO Oncology Committee, 2002). Furthermore, 17–36% of
patients initially treated with low-risk MTX require a change of
chemo-
therapy due to MTX resistance. To date, the most widely used
marker for resistance to single-agent chemotherapy is a plateau or
rise in serum hCG levels, which can obviously occur after several
courses of treatment (Dobson et al, 2000; Garrett et al, 2002;
McNeish et al, 2002; Matsui et al, 2005). Consequently, earlier
detection of patients likely to develop resistance is desirable, so
that more appropriate therapy can be given to cure the disease
rapidly.
Recent work from Van Trommel et al (2006) has identified serum
hCG cutoff points, that allowed early prediction of MTX resistance.
This study was based on hCG levels of 79 patients cured by first-line
MTX. At 97.5% specificity, 50% of low-risk PTD patients not
responding to MTX (n¼29) could be identified just before the start
of the fourth MTX course. Previously, Rotmensch et al (1988)
designed a 90th percentile log-exponential regression curve with
hCG levels of 19 patients successfully treated with MTX.
Other investigators suggested hCG cutoff points determined
by ROC curves for identifying MTX refractory patients based on
hCG regression in MTX responsive patients (Shigematsu et al, 2003).
Prolonged duration of chemotherapy due to belated identifica-
tion of single-agent refractory disease will likely increase stress
levels and adversely affect quality of life because the total duration
of therapy is increased. Although early detection of patients
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sunresponsive to single-agent therapy is favourable, hCG cutoff
levels to identify resistant disease should be stringent, as
starting unnecessary high-risk chemotherapy might elicit severe
toxicities and advance menopause (Rustin et al, 1996; Bower et al,
1998).
Further validation of the study performed by Van Trommel et al
(2006) on serum hCG cutoff levels as a predictor for resistance to
single-agent chemotherapy (developmental study) is required
before clinical implementation. Therefore, the purpose of this
study is to validate and extend the findings obtained from the
Dutch developmental study on prediction of the need for combi-
nation chemotherapy in a larger external British patient cohort, in
a different clinical setting, with serum hCG values obtained using
a different hCG radioimmunoassay (RIA) in an independent
laboratory.
MATERIALS AND METHODS
Study population and setting
Charing Cross Hospital, London, is one of the two centres in the
United Kingdom for treatment of GTD. Between August 1993 and
October 2007, 782 patients were treated with first-line MTX
chemotherapy for low-risk PTD at Charing Cross Hospital.
Exclusion criteria for further analysis are shown in Figure 1. A
total of 655 patients with low-risk PTD, initially treated with
single-agent chemotherapy, were included retrospectively in this
study. Patients with an FIGO 2000 prognostic score p6 (FIGO
Oncology Committee, 2002) were instituted on first-line single-
agent MTX chemotherapy with folinic acid rescue (50mg intra-
muscular MTX on days 1, 3, 5 and 7 with folinic acid 30mg orally
on days 2, 4, 6 and 8, repeated every 2 weeks). Single-agent
chemotherapy drug resistance was defined as two static or rising
hCG levels (study end point). In the United Kingdom, for patients
resistant to MTX, treatment was converted to second-line
chemotherapy according to their hCG level, which is known to
be associated with the amount of remaining trophoblastic tissue.
Patients with MTX refractory disease are treated with second-
line single-agent actinomycin D (hCGp100IUl
 1) or second-line
combination chemotherapy (EMA/CO) in case of hCG levels
4100IUl
 1 at the time of development of MTX resistance. A more
reserved attitude towards treatment with combination chemo-
therapy has been introduced recently (hCG 4100IUl
 1 recently
became 4300IUl
 1 for treatment with combination chemo-
therapy). This may increase the number of patients cured on
single-agent chemotherapy. Actinomycin D (0.5mg on days 1–5,
repeated every 2 weeks) has shown to be a successful single-agent
therapy for MTX resistant PTD, and did not compromise long-
term outcome in patients subsequently requiring third-line
combination chemotherapy (McNeish et al, 2002). Following
normalisation of serum hCG levels (o5IUl
 1), treatment was
continued for another 6 weeks (three consolidation courses),
where after lifelong follow-up of hCG levels proceeded. Low-risk
patients with pulmonary metastasis on chest X-ray received central
nervous system prophylaxis with intrathecal MTX (MTX-IT) in
Flow chart of inclusion criteria of patients initially treated with single-agent MTX  
Exclusion criteria: 
* Non-molar abortion    * Exaggerated placental  
* Ectopic pregnancy        site reaction 
* Twin pregnancy         * Placental site trophoblastic    
* Hydropic abortion         tumour   
n = 26
Study group  
n = 166 (25%) 
* CHM: n = 132  
* PHM: n = 13  
* Unclassified HM: n = 21  
Patients initially treated with MTX  
FIGO 2000 score 6  
Charing Cross Hospital 1993–2007 
n = 782
Low-risk PTD following hydatidiform 




* hCG data not available                   * Second curettage  
* Patients with only hCG levels  * MTX-IT  
* < 3 MTX courses in   < 5 IU l–1 
* Recurrent disease following             control group 
  initial hCG normalisation on MTX    n = 101
Control group 
n = 489 (75%) 
* CHM: n = 386  
* PHM: n = 52  




n = 166 
MTX resistance 
hCG > 100 IU l–1
EMA/CO 
 (including previous 
act. D: n = 16)   
MTX resistance 
hCG < 100 IU l–1 
Second-line act. D: 
hCG normalisation 
n = 92 
First-line MTX: 
hCG normalisation 
n = 397 
Patients responding  
to single-agent 
chemotherapy 
n = 489 
Figure 1 Flow chart of inclusion criteria of patients initially treated with single-agent MTX. MTX¼methotrexate, FIGO¼International Federation for
Obstetrics and Gynecology, PTD¼persistent trophoblastic disease, hCG¼human chorionic gonadotropin, act. D¼actinomycin D, EMA/CO¼etoposide,
MTX, actinomycin D, cyclophosphamide and oncovin, CHM¼complete hydatidiform mole, PHM¼partial hydatidiform mole, MTX-IT¼ intrathecal MTX.
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saddition to the first-line systemic MTX for possible occult cerebral
metastases. Those patients were excluded from further analysis, as
the additional effect of intrathecal MTX on systemic hCG levels
is unknown.
Immunoassays
In the United Kingdom, a non-commercial one-site in-house
competitive hCG RIA using a rabbit polyclonal antibody is utilised
for monitoring GTD. The antibody used in this RIA is directed
to an epitope on the b-subunit and detects all known forms of
b-hCG including free b, intact hCG and b-core fragment with
a comparable cross-reactivity for the different forms of serum
hCG. Furthermore, the antibody is not affected by nicked hCG and
cross-reacts less than 0.25% with luteinising hormone of pituitary
origin. The analytical sensitivity of the assay is 1IUl
 1. Human
chorionic gonadotropin levels less than 5IUl
 1 are considered
normal (Cole and Sutton, 2004).
Statistical methods
Statistical analyses were performed using the SPSS statistical
software package for Microsoft Windows (version 14.0, SPSS Inc,
Chicago, IL, USA). Serum hCG levels were sorted within each MTX
chemotherapy course number and data were excluded for further
analysis from the moment therapy other than MTX started
(hysterectomy, second curettage and second-line chemotherapy).
Normalities of distributions were explored by means of the
Kolmogorov–Smirnov test. Individual serum hCG levels were not
normally distributed, neither with transformations. Therefore, we
performed a non-parametrical analysis by means of ROC curves to
determine hCG cutoff levels (decision threshold) for prediction of
the need for combination chemotherapy (preceding each MTX
course) at 99% specificity. Receiver operating characteristics
curves were obtained from individual serum hCG levels grouped
by MTX course to determine hCG cutoff levels (at 97.5 and 99%
specificity), sensitivity (ie, percentage of patients identified) and
area under curve (AUC). As sensitivity for prediction of the need
for combination chemotherapy was dependent on the specificity
level chosen and the AUC was not, we considered sensitivity to be
the most important outcome measure. To make the results more
accessible, we converted the absolute hCG levels given in IUl
 1
also in percent rates of hCG serum levels. The conversion is based
on 100%¼23667IUl
 1, that is, the median (p50) hCG level of the
study group before the first MTX course. Differences in numerical
parametrical data were calculated by means of the two-tailed
Student’s t-test. Non-parametrical data were assessed by the use of
the two-tailed Mann–Whitney U-test. P-values less than 0.05 were
considered statistically significant. In case of patients o30 in
numbers, data were censored.
RESULTS
A total of 782 patients received single-agent chemotherapy for low-
risk PTD. Six hundred and fifty-five patients with low-risk
persistent disease treated with single-agent chemotherapy between
August 1993 and October 2007 fulfilled the inclusion criteria
shown in Figure 1. Four hundred and eighty-nine patients (75%,
control group) attained remission of trophoblastic disease on
single-agent chemotherapy alone and 166 patients (25%, study
group) required change to a combination chemotherapy regimen
due to single-agent therapy resistance. Among the 489 patients
who achieved remission on single-agent chemotherapy, 92 patients
(18%) achieved remission on second-line single-agent actino-
mycin D following MTX chemotherapy. One hundred and sixty-six
patients required combination chemotherapy, including 16
patients (10%) who previously received second-line actinomycin
D following MTX chemotherapy.
Table 1 describes clinical and therapy-related characteristics
of patients initially treated with single-agent chemotherapy. In
the case of 48 and 19 patients in the control and study
group, respectively, evacuation dates were not available in the
registry’s database. Those patients were not eligible for the analysis
of maternal age and start date of single-agent chemotherapy.
Maternal ages at the time of evacuation did not differ comparing
the control group with the study group. However, start date of
MTX chemotherapy was significantly further from evacuation in
the control group when compared with the study group (median
10 vs 7 weeks, Po0.0001). Overall, for 95% of patients, the first-
line MTX was administered within 26 weeks from evacuation.
As expected, prechemotherapy hCG levels were statistically
lower in the control group than in the study group (median
4614IUl
 1¼19% vs 23667IUl
 1¼100%, Po0.0001). Individuals
from the control group received significantly more MTX courses
than those among the study group (median, six vs four courses,
Po0.0001). The number of patients that received second-line
actinomycin D in the study group (n¼16, median, two courses)
was too low to be compared with the patients that received second-
line actinomycin D in the control group (n¼92, median five
courses). The median number of courses EMA/CO combination
chemotherapy for patients in the study group was five.
Table 2 shows the non-parametric assessment of hCG
cutoff levels by means of ROC curves (represented in Figure 2)
derived from serum hCG levels from patients who gained cure on
single-agent therapy compared with those who required combina-
tion chemotherapy, sorted per MTX course number. We evaluated
hCG cutoff levels and sensitivity both at the 97.5 and 99%
specificity level. Before the start of MTX chemotherapy, 19% of
patients eventually requiring combination chemotherapy could
have been identified by means of hCG cutoff levels (hCG cutoff:
57315IUl
 1¼242%), whereas before the fourth course, sensitivity
increased to 52% (hCG cutoff: 737IUl
 1¼3%) at 97.5% specifi-
city. When using the more strict 99% specificity level to prevent
unnecessary change to combination chemotherapy, sensitivity
decreased, whereas hCG cutoff levels increased. Before the start of
the first MTX course (hCG cutoff: 121664IUl
 1¼514%), 9% of all
MTX-resistant patients could be predicted at 99% specificity. This







Median (range) 30 (18–46) 31 (21–45) NS
a
Start MTX (weeks after evacuation)








Number of courses MTX
Median (range) 6 (3–10) 4 (2–6) o0.0001
a
Number of courses actinomycin D
Median (range) 5 (1–7) 2 (1–5) NA
Number of courses EMA/CO
Median (range) NA 5 (2–11) NA
EMA/CO¼etoposide, MTX, actinomycin D, cyclophosphamide, oncovin; hCG¼
human chorionic gonadotropin; MTX¼methotrexate; NS¼not significant; NA¼
not applicable. Range¼5th to 95th percentile.
aMann–Whitney U-test.
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spercentage increased to 26% before the fourth course (hCG cutoff:
1580IUl
 1¼7%).
Moreover, for single-agent chemotherapy-resistant PTD with
hCG levels exceeding one or more hCG cutoff levels before the
first, second, third, fourth or fifth MTX course at 97.5% specificity,
the number of MTX chemotherapy courses could have been
reduced, in retrospect, by an average of 2.5 MTX courses (range,
1–9 courses). In case the hCG cutoff levels at 99% specificity
would have been applied, an average of 2.1 MTX courses (range,
1–6) could have been saved. These data are not shown in Table 2.
Figure 3 illustrates hCG cutoff levels derived from ROC analysis
based on serum hCG regression in the study group, when
compared with the hCG levels among the control group. For
patients with hCG levels in the dark grey area, the need for
combination chemotherapy could be predicted by means of
exceeding the hCG cutoff levels when specificity was set at 99%.
Patients with hCG levels in the medium grey area could
additionally be identified in case hCG cutoff levels at 97.5%
specificity would have been applied. Patients with hCG levels in
the light grey area could not be predicted by exceeding of
the hCG cutoff levels at 97.5 or 99% specificity. In addition to
absolute hCG levels, the Y-axis shows the hCG levels converted
to percent rates, based on 100%¼23667IUl
 1, that is, the median
of serum hCG levels among the study group before the first
MTX course.
DISCUSSION
The purpose of this study was to validate the Dutch developmental
study on prediction of the need for combination chemotherapy by
means of hCG cutoff levels performed by Van Trommel et al
(2006) using a much larger retrospective PTD patient data set from
a different organisation with a distinct hCG assay. A six times
larger patient number in the present validation study enabled us to
refine the model for determining hCG cutoff levels as developed
earlier by Van Trommel et al (2006). First, to reduce the false-
positive diagnosis of single-agent chemotherapy resistance, we
calculated the specificity level at 99% in addition to the 97.5%
specificity level. A further adjustment of the calculations
performed by Van Trommel et al (2006) was the removal of all
hCG levels from the moment of hCG normalisation in the control
group. This is because, in the prospective setting, patients who
achieve normalisation are not considered for further treatment.
Consequently, hCG cutoff levels increased, and there was a slight
decrease in the calculated predictive value for MTX resistance
relative to that of a calculation including all normal hCG levels.
The last refinement in the model for determining hCG cutoff levels
for prediction of MTX resistance is that we have calculated those
hCG cutoff levels by non-parametric analysis only, as the present
serum hCG data were not normally distributed, whereas Van
























Figure 2 Receiver operating characteristics curves of serum hCG levels
in patients requiring combination chemotherapy (study group) compared
with hCG levels among the patients cured on single-agent chemotherapy
(control group) before the first, third, fourth and fifth MTX course (MTX 1,




99th percentile study group
hCG cut-off at 99% specificity
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Figure 3 Serum hCG regression in patients requiring combination
chemotherapy (study group) compared with serum hCG cutoff levels at 99
and 97.5% specificity based on ROC analysis of hCG levels among the
study vs the control group. hCG¼human chorionic gonadotropin,
MTX¼methotrexate.
Table 2 AUC and sensitivity at 97.5 and 99% specificity based on ROC curves of serum hCG levels before the start of MTX chemotherapy (MTX 1) and
before the third, fourth and fifth MTX course (MTX 3, 4 and 5)
MTX 1 MTX 3 MTX 4 MTX 5
Control group (n) 489 466 285 169
hCG cutoff (IUl
 1) at 97.5% specificity 57315 2269 737 304
hCG cutoff (IUl
 1) at 99% specificity 121664 6433 1580 600
Study group (n) 166 148 98 30
AUC (95% CI) 0.75 (0.71–0.79) 0.86 (0.83–0.93) 0.89 (0.86–0.93) 0.87 (0.80–0.95)
Sensitivity at 97.5% specificity 19% 43% 52% 67%
Sensitivity at 99% specificity 9% 20% 26% 30%
AUC¼area under curve; CI¼confidence interval; hCG¼human chorionic gonadotropin; ROC¼receiver operator characteristics.
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sregression lines) and non-parametric assessment (derived from
ROC analysis).
One-fourth of all patients initially treated for low-risk PTD
with single-agent chemotherapy subsequently required combina-
tion chemotherapy. For those patients requiring combination
chemotherapy, serum hCG cutoff levels could predict 26%
of single-agent chemotherapy-resistant patients before the fourth
MTX course at 99% specificity. Interestingly, a 1.5% decrease in
specificity (from 99 to 97.5%) gives rise to a two times higher
sensitivity (from 26 to 52%), although earlier identification of
patients requiring combination chemotherapy at the expense of a
decrease in specificity (ie, false-positive diagnosis of single-agent
chemotherapy refractory disease) is unfavourable. For MTX
refractory patients with one or more serum hCG levels exceeding
the hCG cutoff levels before the first, second, third, fourth or fifth
MTX course at 97.5% specificity, the number of MTX chemother-
apy courses could have been reduced, in retrospect, by an average
of 2.5 courses (range, 1–9). Comparison of absolute hCG cutoff
levels of this study with hCG cutoff levels derived from the
developmental study of Van Trommel et al (2006) is not
applicable, as a different RIA was used, with different sensitivity,
specificity and cross-reactivity. Confirmatory data using a
distinct much larger patient cohort with another RIA of course
further strengthens our model. Using hCG cutoff levels at 97.5%
specificity, we found that 52% of patients resistant to single-agent
chemotherapy could be identified before the fourth MTX course,
which is comparable to 50% of MTX-resistant patients predictable
in the Dutch developmental study. The percentage of MTX-
resistant patients identified by means of hCG cutoff levels might be
influenced by the low number of MTX-resistant patients in the
Dutch cohort (n¼29) and a 10 times higher cross-reactivity for
b-hCG in the Dutch assay, which may overestimate the difference
in hCG levels between MTX responsive and resistant patients and
the method of assessment of hCG cutoff levels. Also, in this study,
the control group consisted of patients cured on single-agent
chemotherapy (including MTX and actinomycin D), whereas the
control group in the developmental study consisted of patients
cured on MTX solely. The serum hCG levels among the subgroup
who received MTX-only were comparable to those observed in the
total single-agent chemotherapy group. The higher median
number of MTX courses in the Dutch group than in the Charing
Cross group of patients eventually requiring combination chemo-
therapy (seven vs four courses of first-line MTX) suggest a more
proactive approach towards change to combination therapy in
the latter.
Prospective testing of a parameter on an independent set
of patients in a multicentre setting is the ultimate test a parameter
has to go through before reaching the level of evidence (LOE)
type I according to the Tumor Marker Utility Grading Scale as
introduced by Hayes et al (1996). Because of the retrospective
nature of our external validation study, we considered the LOE to
be III out of V. Unfortunately, a prospective study is impracticable,
as low-risk PTD is a rare condition. Confounding factors due to the
retrospective nature of this study were for instance different
criteria for low-risk disease in force at the time. However, MTX
treatment protocols and criteria for MTX resistance did not
diverge within this study, enabled by centralised treatment of PTD
at one specialized centre. Although LOE type I is not reached, we
consider our parameter suitable for the application in the routine
clinical practice.
In this study, 39% of patients initially classified as low-risk PTD,
developed resistance to MTX, an apparent increase compared with
resistance rates reported by the Charing Cross Hospital before
(1989: 20%, 2002: 31%; Bagshawe et al, 1989; McNeish et al, 2002).
In 1989, patients were classified as low-risk PTD with a Charing
Cross score from 0 to 5 (p8 corresponds to an FIGO score p6)
(Bagshawe et al, 1989). The subsequent inclusion of the former
medium risk group of patients scoring 6–8 on the Charing Cross
Score likely accounts for the increased MTX resistance was seen.
Indeed, the report from 2002 included several patients who were
classified as low-risk PTD with a Charing Cross score between
0 and 8 (McNeish et al, 2002). This study incorporated more
patients who were classified as low-risk PTD by the revised
classification, resulting in a higher proportion of higher prognostic
risk scores, and thus an increased MTX resistance rate.
In conclusion, we confirm the earlier observation by Van
Trommel et al (2006) that hCG cutoff levels are useful for the
prediction of resistance to single-agent chemotherapy. Change to
combination chemotherapy should be considered for patients
whose serum hCG levels exceed the cutoff levels. For patients not
exceeding the hCG cutoff levels, static or rising hCG levels should
still be included in the criteria for change of chemotherapeutic
regimen following single-agent chemotherapy. Our model of
prediction of the need for combination chemotherapy proved to
be valid on an independent group of patients with hCG values
obtained using a different hCG assay.
REFERENCES
Bagshawe KD, Dent J, Newlands ES, Begent RH, Rustin GJ (1989) The role
of low-dose methotrexate and folinic acid in gestational trophoblastic
tumours (GTT). Br J Obstet Gynaecol 96: 795–802
Bower M, Rustin GJ, Newlands ES, Holden L, Short D, Foskett M, Bagshawe
KD (1998) Chemotherapy for gestational trophoblastic tumours hastens
menopause by 3 years. Eur J Cancer 34: 1204–1207, doi:10.1016/
S0959-8049(98)00059-8
Cole LA, Sutton JM (2004) Selecting an appropriate hCG test for
managing gestational trophoblastic disease and cancer. J Reprod Med
49: 545–553
Delfs E (1957) Quantitative chorionic gonadotropin: prognostic value in
hydatidiform mole and chorionepithelioma. Obstet Gynecol 9: 1–23
Dobson LS, Lorigan PC, Coleman RE, Hancock BW (2000) Persistent
gestational trophoblastic disease: results of MEA (methotrexate, etopo-
side and dactinomycin) as first-line chemotherapy in high-risk disease
and EA (etoposide and dactinomycin) as second-line therapy for low risk
disease. Br J Cancer 82: 1547–1552, doi:10.1054/bjoc.2000.1176
FIGO Oncology Committee (2002) FIGO staging for gestational tropho-
blastic neoplasia 2000. Int J Gynaecol Obstet 77: 285–287, doi:10.1016/
S0020-7292(02)00063-2
Garrett AP, Garner EO, Goldstein DP, Berkowitz RS (2002) Methotrexate
infusion and folinic acid as primary therapy for nonmetastatic and
low-risk metastatic gestational trophoblastic tumors. 15 years of
experience. J Reprod Med 47: 355–362
Hayes DF, Bast RC, Desch CE, Fritsche Jr H, Kemeny NE, Jessup JM, Locker
GY, Macdonald JS, Mennel RG, Norton L, Ravdin P, Taube S, Winn RJ
(1996) Tumor marker utility grading system: a framework to evaluate
clinical utility of tumor markers. J Nat Cancer Inst 88: 1456–1466
Matsui H, Suzuka K, Yamazawa K, Tanaka N, Mitsuhashi A, Seki K,
Sekiya S (2005) Relapse rate of patients with low-risk gestational
trophoblastic tumor initially treated with single-agent chemotherapy.
Gynecol Oncol 96: 616–620, doi:10.1016/j.ygyno.2004.11.011
McNeish IA, Strickland S, Holden L, Rustin GJ, Foskett M, Seckl MJ,
Newlands ES (2002) Low-risk persistent gestational trophoblastic
disease: outcome after initial treatment with low-dose methotrexate
and folinic acid from 1992 to 2000. J Clin Oncol 20: 1838–1844,
doi:10.1200/JCO.2002.07.166
Rotmensch J, Rosenhein NB, Block BS (1988) Comparison of human
chorionic gonadotropin regression in molar pregnancies and post-molar
nonmetastatic gestational trophoblastic neoplasia. Gynecol Oncol 29: 82–86
Rustin GJ, Newlands ES, Lutz JM, Holden L, Bagshawe KD, Hiscox JG,
Foskett M, Fuller S, Short D (1996) Combination but not single-agent
methotrexate chemotherapy for gestational trophoblastic tumors
increases the incidence of second tumors. J Clin Oncol 14: 2769–2773
Prediction of chemotherapy resistance in PTD
LG Kerkmeijer et al
983




















sSeckl MJ, Fisher RA, Salerno G, Rees H, Paradinas FJ, Foskett M, Newlands
ES (2000) Choriocarcinoma and partial hydatidiform moles. Lancet 356:
36–39, doi:10.1016/S0140-6736(00)02432-6
Shigematsu T, Hirakawa T, Yahata H, Sonoda T, Kinukawa N, Nakano H
(2003) Identification of chemotherapeutic refractory cases based on
human chorionic gonadotropin values among patients with low-risk
persistent trophoblastic disease treated with 8-day methotrexate-folinic
acid. Eur J Gynaecol Oncol 24: 113–116
Van Trommel NE, Massuger LF, Schijf CP, ten Kate-Booij MJ, Sweep FC,
Thomas CM (2006) Early identification of resistance to first-line single-
agent methotrexate in patients with persistent trophoblastic disease.
J Clin Oncol 24: 52–58, doi:10.1200/JCO.2005.03.3043
Wolfberg AJ, Feltmate C, Goldstein DP, Berkowitz RS, Lieberman E (2004)
Low risk of relapse after achieving undetectable hCG levels in women
with complete molar pregnancy. Obstet Gynecol 104: 551–554,
doi:10.1097/01.AOG.0000136099.21216.45
Prediction of chemotherapy resistance in PTD
LG Kerkmeijer et al
984
British Journal of Cancer (2009) 100(6), 979–984 & 2009 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
s